Point Therapeutics Provides Clinical Update During Recent Company Webcast; Additional Clinical Responses Observed in the Phase 2
February 02 2006 - 7:30AM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) announced during a January
31, 2006 Webcast an additional clinical response in both its
metastatic non-small cell lung cancer (NSCLC) and metastatic
melanoma combination Phase 2 studies. In the Phase 2 metastatic
NSCLC study combining talabostat with docetaxel, this additional
responder now brings the total number of observed clinical
responses to six, for an overall response rate of 14.3%. Of the six
responding patients, two experienced complete responses. The two
complete responses have persisted for at least 8 months. In
addition, of the first 40 patients enrolled in the study, 48% have
survived for at least 12 months. In the Phase 2 metastatic melanoma
study combining talabostat with cisplatin, an additional clinical
response was also observed. Five total responses have been observed
thus far in the study, for an overall response rate of 11.9%. "We
are very pleased by the clinical activity shown by talabostat thus
far in all of our Phase 2 trials. These results are especially
noteworthy because of the advanced stage of disease of the patients
in our trials," said Dr. Margaret Uprichard, Senior Vice President,
Chief Development Officer of Point. In addition to the clinical
update, Don Kiepert, President and CEO of Point gave an update on
the commercial strategy for the company. "Securing a strategic
alliance is the company's top business priority for 2006. As an
organization, we are committed to finding the right partner to help
support the clinical program and the marketing and distribution of
talabostat. We are making good progress in this area. We are
currently discussing the talabostat program with several potential
partners and are targeting a collaboration in the second half of
2006," said Kiepert. Based on the clinical efficacy shown in the
NSCLC Phase 2 trial, Point Therapeutics announced that it is
enrolling patients in two randomized, placebo-controlled,
double-blind Phase 3 studies. One Phase 3 study is evaluating
talabostat and docetaxel versus placebo and docetaxel. The other is
evaluating talabostat and pemetrexed versus placebo and pemetrexed.
Both studies will enroll 400 patients each, 200 patients per
treatment arm. About Point Therapeutics, Inc.: Point is a
Boston-based biopharmaceutical company developing a portfolio of
dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2
diabetes and as vaccine adjuvants. Point is currently studying its
lead product candidate, talabostat, in a Phase 3 trial in NSCLC.
Point is also studying talabostat in several Phase 2 trials,
including as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with
rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as
a vaccine adjuvant. Certain statements contained herein are not
strictly historical and are "forward looking" statements as defined
in the Private Securities Litigation Reform Act of 1995. This
information includes statements with respect to the company's
clinical development programs and the timing of initiation and
completion of its clinical trials. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "feels," "expects," "may," "will," "should," "seeks,"
"plans," "schedule to," "anticipates" or "intends" or the negative
of those terms, or other variations of those terms of comparable
language, or by discussions of strategy or intentions. A number of
important factors could cause actual results to differ materially
from those projected or suggested in the forward looking statement,
including the risk factors described in Point's quarterly report on
Form 10-Q for the quarter ended September 30, 2005 and from time to
time in Point's periodic and other reports filed with the
Securities and Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Oct 2023 to Oct 2024